Update: Samsung Biologics manufacture Pfizer's biosimilars
Samsung Biologics agrees to use their biocampus Plant 4 for the manufacture of a line of products from Pfizer.
In a big step to strengthen partnerships and expand manufacturing capabilities, Samsung Biologics have entered into an agreement with Pfizer to take over the long-term commercial manufacturing of Pfizer’s portfolio.
In March 2023 the two companies signed an agreement stating that Samsung Biologics would start manufacturing one of Pfizer’s products, now this new deal encompasses multiple products from Pfizer. The product portfolio is extensive, including in the fields of inflammation, immunology, and oncology.
Samsung Biologics will use their most recently operational manufacturing plant, Plant 4, to manufacture the Pfizer product portfolio. This was the first plant developed as a bio campus, which will be closely followed by the in-progress Plant 5, and then through to Plant 8. The partnership will serve to massively increase Pfizer’s capacity for large-scale manufacturing of their biosimilars products.
“We are pleased to extend the strategic collaboration with Pfizer as we share and support their strong vision to bring innovative solutions for patients around the globe,” commented John Rim, President and CEO of Samsung Biologics. “This new meaningful partnership comes just as our Plant 4 is fully completed early this month as we had previously committed and are on the move for future expansion into our second campus in order to provide our clients with even more flexible and advanced manufacturing technology.”
“Pfizer is excited to continue our strategic partnership with Samsung Biologics Ltd. that aims to enable greater access to medicines for more patients across the world,” stated Mike McDermott, Chief Global Supply Officer and Executive Vice President at Pfizer. “This commitment is a reflection of Pfizer’s trust in the Korean Pharmaceutical industry to address emerging health challenges.”
“Our collaboration with Samsung Biologics will have the potential to significantly improve the lives of patients globally,” added Dong-Wook Oh, Pfizer Korea Country Manager.
Update
Only July 3, Samsung Biologics and Pfizer signed two mega deals for the long-term manufacturing of Pfizer's biosimilar portfolio totaling USD $897m. The products will be manufactured at Samsung Biologics' newest Plant 4 manufacturing facility in South Korea with the world's largest manufacturing capacity at a single site, boasting 240,000 litres. The deals are expected to last through to 2029.
Related News
-
News CPHI Online Trend Report: what is pharmaceutical packaging really costing the industry?
The latest CPHI Online Trend Report dives into what it really costs to develop, manufacture, and deploy pharmaceutical packaging that balances sustainability concerns, patient safety, and drug efficacy. -
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance